Business Context and Reporting Period
This Form 6-K filing by Addex Therapeutics Ltd. covers the month of December 2021, specifically dated December 17, 2021. The filing discloses a Registered Direct Offering and a Concurrent Private Placement entered into on December 16, 2021, with an institutional investor to raise capital for the Company's operations.
Key Financial Metrics and Offering Details
- Gross Proceeds: Expected aggregate gross proceeds of $10.0 million.
- Offering Price: $6.50 per American Depositary Share (ADS), equivalent to CHF 1.00 per share.
- Registered Direct Offering: Sale of 3,752,202 shares (625,367 ADSs).
- Private Placement Warrants:
- Unregistered Warrants to purchase up to 9,230,772 shares (1,538,462 ADSs) at an exercise price of $6.50 per ADS, exercisable 60 days after issuance and expiring in six years.
- Unregistered Pre-Funded Warrants to purchase up to 5,478,570 shares (913,095 ADSs) at an exercise price of $0.01 per ADS, exercisable immediately.
- Transaction Costs:
- Placement agent fee: 6.75% of aggregate gross proceeds (excluding warrant exercise proceeds).
- Management fee: 1.0% of aggregate gross proceeds.
- Reimbursement of legal and other expenses: Up to $100,000 for legal and $30,950 for other expenses.
Note: The filing does not provide specific revenue, profit, cash flow, margin, or existing debt figures for the reporting period.
Material Changes and Terms
The primary material change is the dilution of existing shareholders due to the issuance of new shares and warrants. The Company has agreed to a lock-up provision restricting the issuance of new securities for 90 days post-closing or until the resale registration statement is effective, whichever is later. Additionally, the investor has been granted a 50% participation right in any subsequent equity financing for 18 months following the closing of this offering.
Outlook, Risks, and Management Commentary
The Offering is expected to close on or about December 21, 2021, subject to customary closing conditions. The Company intends to file a Form F-1 registration statement to allow the shares underlying the Purchase Warrants to be freely tradeable in the United States. The filing includes standard forward-looking statements regarding the consummation of the offering and the use of proceeds, noting that actual results may differ due to market conditions and other risks detailed in the Company's Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the final closing date of the offering (expected December 21, 2021) and the actual net proceeds received after fees.
- Confirm the effectiveness of the Resale Registration Statement (Form F-1) to determine when warrant shares become freely tradeable.
- Review the Company's latest Form 20-F for updated risk factors and current cash position to assess liquidity post-offering.
- Monitor for any subsequent equity financings within the 18-month window to understand the impact of the investor's 50% participation right.